Overview
- The MHRA has granted marketing authorisation for depemokimab, to be sold as Exdensur, for patients with severe, uncontrolled asthma.
- The injection is administered under the skin once every six months, a longer interval than existing biologic treatments given every two to eight weeks.
- In a 762-patient trial, the drug cut hospital admissions by about 72 percent and reduced clinically significant exacerbations by 54 percent.
- GSK plans to make Exdensur available for private purchase in the UK in the first half of 2026, while NICE decides next year on NHS prescribing.
- Experts say uptake will hinge on GSK’s pricing and current NICE criteria requiring at least three severe attacks a year, with only about 21,000 of an estimated 58,000 eligible adults receiving biologics today.